Strides Pharma Science LtdNSE: STAR

Press Release (Revised) Oct 03 2023

· Issued by Strides Pharma Science Ltd

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Strides Pharma Science Ltd has issued an updated press release regarding its recent USFDA approval for Icosapent Ethyl Capsules. The revised press release includes additional information about the product and its market opportunity. The capsules are bioequivalent to the reference drug and will be manufactured at the company's facility in Bengaluru. Strides aims to launch a significant number of new products in the US market over the next few years.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Strides Pharma Science Limited has informed the Exchange regarding a revised press release dated October 03, 2023, titled "This has reference to the Press Release issued by the Company on September 23, 2023 titled as Strides receives USFDA approval for Icosapent Ethyl Capsules The said press release has been updated with some additional information on the Product and the revised Press release is attached herewith for your records.".

Strides Pharma Science Ltd on 6ix

Earlier from Strides Pharma Science

Later from Strides Pharma Science

All Strides Pharma Science news releases